Do inhibitory immune receptors play a role in the etiology of autoimmune disease?

Clinical Immunology

Volumn 150, Issue 1, 2014, Pages 31-42

  Olde Nordkamp, Marloes J M ^a   Koeleman, Bobby P ^a   Meyaard, Linde ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Autoimmune disease; Downstream effectors; GWAS; Inhibitory immune receptor; Mouse models

Indexed keywords

CARBOXYL TERMINAL SRC KINASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CD200 RECEPTOR; CD22 ANTIGEN; CD31 ANTIGEN; CD94 ANTIGEN; COLLAGEN ANTIBODY; CYTOCHROME P450 2B4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR IIB; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL2; LECTIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PHOSPHOTRANSFERASE; PROGRAMMED DEATH 1 RECEPTOR; REGULATOR PROTEIN; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGNAL REGULATORY PROTIEN ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BASOPHIL; BEHCET DISEASE; CD8+ T LYMPHOCYTE; CELIAC DISEASE; COPY NUMBER VARIATION; CROHN DISEASE; DENDRITIC CELL; DISEASE SEVERITY; ENDOTHELIUM CELL; EOSINOPHIL; GAMMA DELTA T LYMPHOCYTE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GRAVES DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KERATINOCYTE; MACROPHAGE; MAST CELL; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NERVE CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA CELL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE; TROPHOBLAST; ULCERATIVE COLITIS;

AUTOIMMUNE DISEASE; DOWNSTREAM EFFECTORS; GWAS; INHIBITORY IMMUNE RECEPTOR; MOUSE MODELS;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; RECEPTORS, IMMUNOLOGIC;

EID: 84890037323     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.11.007     Document Type: Review

References (119)

1. Pritchard N.R., Smith K.G. B cell inhibitory receptors and autoimmunity. Immunology 2003, 108:263-273.
2. Vivier E., Daeron M. Immunoreceptor tyrosine-based inhibition motifs. Immunol. Today 1997, 18:286-291.
3. Verbrugge A., Rijkers E.S.K., De Ruiter T., Meyaard L. Leukocyte-associated Ig-like receptor-1 has SH-2 domain-containing phosphatase-independent function and recruits C-terminal Src kinase. Eur. J. Immunol. 2006, 36:190-198.
4. Sayos J., Martinez-Barriocanal A., Kitzig F., Bellon T., Lopez-Botet M. Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j. Biochem. Biophys. Res. Commun. 2004, 324:640-647.
5. Veillette A., Thibaudeau E., Latour S. High expression of inhibitory receptor SHPS-1 and its association with protein-tyrosine phosphatase SHP-1 in macrophages. J. Biol. Chem. 1998, 273:22719-22728.
6. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
7. Schmetterer K.G., Neunkirchner A., Pickl W.F. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J. 2012, 26:2253-2276.
8. Daeron M., Jaeger S., Du Pasquier L., Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol. Rev. 2008, 224:11-43.
9. Jansen C.A., Cruijsen C., De Ruiter T., Nanlohy N., Willems N., Janssens-Corpela P., et al. Regulated expression of the inhibitory receptor LAIR-1 on human peripheral T cells during T cell activation and differentiation. Eur. J. Immunol. 2007, 37:914-924.
10. Verbrugge A., De Ruiter T., Geest C., Coffer P.J., Meyaard L. Differential expression of leukocyte associated Ig-like receptor-1 during neutrophil differentiation and activation. J. Leukoc. Biol. 2006, 79:828-836.
11. Trentham D.E., Townes A.S., Kang A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 1977, 146:857-868.
12. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283:666-668.
13. Nandakumar K.S. Pathogenic antibody recognition of cartilage. Cell Tissue Res. 2010, 339:213-220.
14. Yuasa T., Kubo S., Yoshino T., Ujike A., Matsumura K., Ono M., et al. Deletion of fcgamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J. Exp. Med. 1999, 189:187-194.
15. Wong M.X., Hayball J.D., Hogarth P.M., Jackson D.E. The inhibitory co-receptor, PECAM-1 provides a protective effect in suppression of collagen-induced arthritis. J. Clin. Immunol. 2005, 25:19-28.
16. Simelyte E., Alzabin S., Boudakov I., Williams R. CD200R1 regulates the severity of arthritis but has minimal impact on the adaptive immune response. Clin. Exp. Immunol. 2010, 162:163-168.
17. Fujikado N., Saijo S., Yonezawa T., Shimamori K., Ishii A., Sugai S., et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat. Med. 2008, 14:176-180.
18. Helenius L.M., Hietanen J.H., Helenius I., Kautiainen H., Piirainen H., Paimela L., et al. Focal sialadenitis in patients with ankylosing spondylitis and spondyloarthropathy: a comparison with patients with rheumatoid arthritis or mixed connective tissue disease. Ann. Rheum. Dis. 2001, 60:744-749.
19. Levin S.D., Taft D.W., Brandt C.S., Bucher C., Howard E.D., Chadwick E.M., et al. Vstm3 is a member of the CD28 family and an important modulator of T-cell function. Eur. J. Immunol. 2011, 41:902-915.
20. Good-Jacobson K.L., Szumilas C.G., Chen L., Sharpe A.H., Tomayko M.M., Shlomchik M.J. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat. Immunol. 2010, 11:535-542.
21. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
22. Rivers T.M., Sprunt D.H., Berry G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58:39-53.
23. Batoulis H., Recks M.S., Addicks K., Kuerten S. Experimental autoimmune encephalomyelitis-achievements and prospective advances. APMIS 2011, 119:819-830.
24. Graesser D., Solowiej A., Bruckner M., Osterweil E., Juedes A., Davis S., et al. Altered vascular permeability and early onset of experimental autoimmune encephalomyelitis in PECAM-1-deficient mice. J. Clin. Investig. 2002, 109:383-392.
25. Xi H., Katschke K.J., Helmy K.Y., Wark P.A., Kljavin N., Clark H., et al. Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1. J. Exp. Med. 2010, 207:7-16.
26. Alvarez-Errico D., Aguilar H., Kitzig F., Brckalo T., Sayos J., Lopez-Botet M. IREM-1 is a novel inhibitory receptor expressed by myeloid cells. Eur. J. Immunol. 2004, 34:3690-3701.
27. Hoek R.M., Ruuls S.R., Murphy C.A., Wright G.J., Goddard R., Zurawski S.M., et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290:1768-1771.
28. Carter L.L., Leach M.W., Azoitei M.L., Cui J., Pelker J.W., Jussif J., et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2007, 182:124-134.
29. Watanabe N., Gavrieli M., Sedy J.R., Yang J., Fallarino F., Loftin S.K., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol. 2003, 4:670-679.
30. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
31. Fujita M., Otsuka T., Mizuno M., Tomi C., Yamamura T., Miyake S. Carcinoembryonic antigen-related cell adhesion molecule 1 modulates experimental autoimmune encephalomyelitis via an iNKT cell-dependent mechanism. Am. J. Pathol. 2009, 175:1116-1123.
32. Hurwitz A.A., Sullivan T.J., Krummel M.F., Sobel R.A., Allison J.P. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J. Neuroimmunol. 1997, 73:57-62.
33. Hurwitz A.A., Sullivan T.J., Sobel R.A., Allison J.P. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:3013-3017.
34. Jorgensen T.N., Gubbels M.R., Kotzin B.L. Links between type I interferons and the genetic basis of disease in mouse lupus. Autoimmunity 2003, 36:491-502.
35. Bolland S., Ravetch J.V. Spontaneous autoimmune disease in Fc(gamma)RIIB-deficient mice results from strain-specific epistasis. Immunity 2000, 13:277-285.
36. Pritchard N.R., Cutler A.J., Uribe S., Chadban S.J., Morley B.J., Smith K.G. Autoimmune-prone mice share a promoter haplotype associated with reduced expression and function of the Fc receptor FcgammaRII. Curr. Biol. 2000, 10:227-230.
37. O'Keefe T.L., Williams G.T., Batista F.D., Neuberger M.S. Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J. Exp. Med. 1999, 189:1307-1313.
38. Jellusova J., Wellmann U., Amann K., Winkler T.H., Nitschke L. CD22×Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity. J. Immunol. 2010, 184:3618-3627.
39. Wilkinson R., Lyons A.B., Roberts D., Wong M.X., Bartley P.A., Jackson D.E. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) acts as a regulator of B-cell development, B-cell antigen receptor (BCR)-mediated activation, and autoimmune disease. Blood 2002, 100:184-193.
40. Cunnane G., Chan O.T., Cassafer G., Brindis S., Kaufman E., Yen T.S., et al. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum. 2004, 50:1539-1548.
41. Ichinose K., Zhang Z., Koga T., Juang Y.T., Kis-Toth K., Sharpe A.H., et al. Brief report: increased expression of a short splice variant of CTLA-4 exacerbates lupus in MRL/lpr mice. Arthritis Rheum. 2013, 65:764-769.
42. Boross P., Arandhara V.L., Martin-Ramirez J., Santiago-Raber M.L., Carlucci F., Flierman R., et al. The inhibiting Fc receptor for IgG, FcgammaRIIB, is a modifier of autoimmune susceptibility. J. Immunol. 2011, 187:1304-1313.
43. Tang X., Tian L., Esteso G., Choi S.C., Barrow A.D., Colonna M., et al. Leukocyte-associated Ig-like receptor-1-deficient mice have an altered immune cell phenotype. J. Immunol. 2012, 188:548-558.
44. Okuzawa C., Kaneko Y., Murata Y., Miyake A., Saito Y., Okajo J., et al. Resistance to collagen-induced arthritis in SHPS-1 mutant mice. Biochem. Biophys. Res. Commun. 2008, 371:561-566.
45. Tomizawa T., Kaneko Y., Kaneko Y., Saito Y., Ohnishi H., Okajo J., et al. Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice. J. Immunol. 2007, 179:869-877.
46. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
47. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
48. Monsivais-Urenda A., Nino-Moreno P., bud-Mendoza C., Baranda L., Layseca-Espinosa E., Lopez-Botet M., et al. Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J.Autoimmun. 2007, 29:97-105.
49. Young N.T., Uhrberg M., Phillips J.H., Lanier L.L., Parham P. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J. Immunol. 2001, 166:3933-3941.
50. Colonna M., Navarro F., Lopez-Botet M. A novel family of inhibitory receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. Curr. Top. Microbiol. Immunol. 1999, 244:115-122.
51. Saverino D., Fabbi M., Ghiotto F., Merlo A., Bruno S., Zarcone D., et al. The CD85/LIR-1/ILT2 inhibitory receptor is expressed by all human T lymphocytes and down-regulates their functions. J. Immunol. 2000, 165:3742-3755.
52. Mackay M., Stanevsky A., Wang T., Aranow C., Li M., Koenig S., et al. Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE. J. Exp. Med. 2006, 203:2157-2164.
53. Carreno L.J., Pacheco R., Gutierrez M.A., Jacobelli S., Kalergis A.M. Disease activity in systemic lupus erythematosus is associated with an altered expression of low-affinity Fc gamma receptors and costimulatory molecules on dendritic cells. Immunology 2009, 128:334-341.
54. Radstake T.R., Blom A.B., Sloetjes A.W., van Gorselen E.O., Pesman G.J., Engelen L., et al. Increased FcgammaRII expression and aberrant tumour necrosis factor alpha production by mature dendritic cells from patients with active rheumatoid arthritis. Ann. Rheum. Dis. 2004, 63:1556-1563.
55. Colombo B.M., Canevali P., Magnani O., Rossi E., Puppo F., Zocchi M.R., et al. Defective expression and function of the leukocyte associated Ig-like receptor 1 in B lymphocytes from systemic lupus erythematosus patients. PLoS ONE 2012, 7:e31903.
56. Olde Nordkamp M.J.M., van Roon J.A., Douwes M., De Ruiter T., Urbanus R.T., Meyaard L. Enhanced secretion of leukocyte-associated immunoglobulin-like receptor (LAIR)-2 and soluble LAIR-1 in rheumatoid arthritis: LAIR-2 is a more efficient antagonist of the LAIR-1-collagen inhibitory interaction than soluble LAIR -1. Arthritis Rheum. 2011, 63:3749-3757.
57. Lebbink R.J., van den Berg M.C., de R T., Raynal N., van Roon J.A., Lenting P.J., et al. The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction. J. Immunol. 2008, 180:1662-1669.
58. Wang L., Kang N., Zhou J., Guo Y., Zhang X., Cui L., et al. Downregulation of CD94/NKG2A inhibitory receptor on decreased gammadelta T cells in patients with systemic lupus erythematosus. Scand. J. Immunol. 2012, 76:62-69.
59. Walsh C.E., Ryan E.J., O'Farrelly C., Golden-Mason L., FitzGerald O., Veale D.J., et al. Differential expression of NK receptors CD94 and NKG2A by T cells in rheumatoid arthritis patients in remission compared to active disease. PLoS ONE 2011, 6:e27182.
60. Cannons J.L., Tangye S.G., Schwartzberg P.L. SLAM family receptors and SAP adaptors in immunity. Annu. Rev. Immunol. 2011, 29:665-705.
61. Kim J.R., Mathew S.O., Patel R.K., Pertusi R.M., Mathew P.A. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin. Exp. Immunol. 2010, 160:348-358.
62. Li Y., Zhao L.D., Tong L.S., Qian S.N., Ren Y., Zhang L., et al. Aberrant CD200/CD200R1 expression and function in systemic lupus erythematosus contributes to abnormal T-cell responsiveness and dendritic cell activity. Arthritis Res. Ther. 2012, 14:R123.
63. Jury E.C., Flores-Borja F., Kalsi H.S., Lazarus M., Isenberg D.A., Mauri C., et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. Eur. J. Immunol. 2010, 40:569-578.
64. Hastings W.D., Anderson D.E., Kassam N., Koguchi K., Greenfield E.A., Kent S.C., et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur. J. Immunol. 2009, 39:2492-2501.
65. Yang L., Anderson D.E., Kuchroo J., Hafler D.A. Lack of TIM-3 immunoregulation in multiple sclerosis. J. Immunol. 2008, 180:4409-4414.
66. Meyaard L., Smyth M.J. Liberating tumor immunity. Curr. Opin. Immunol. 2012, 24:204-206.
67. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
68. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
69. Pritchard J.K., Cox N.J. The allelic architecture of human disease genes: common disease-common variant. .or not?. Hum. Mol. Genet. 2002, 11:2417-2423.
70. Dudbridge F., Gusnanto A. Estimation of significance thresholds for genomewide association scans. Genet. Epidemiol. 2008, 32:227-234.
71. Pe'er I., Yelensky R., Altshuler D., Daly M.J. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 2008, 32:381-385.
72. Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European Bioinformatics Institute), Junkins HA, Hall PN, Klemm AK et al. A catalog of published genome-wide association studies. 2013.
73. Barrett J.C., Clayton D.G., Concannon P., Akolkar B., Cooper J.D., Erlich H.A., et al. Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat. Genet. 2009, 41:703-707.
74. Qu H.Q., Bradfield J.P., Grant S.F., Hakonarson H., Polychronakos C. Remapping the type I diabetes association of the CTLA4 locus. Genes Immun. 2009, 10(Suppl. 1):S27-S32.
75. Cooper J.D., Smyth D.J., Smiles A.M., Plagnol V., Walker N.M., Allen J.E., et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat. Genet. 2008, 40:1399-1401.
76. Gregersen P.K., Amos C.I., Lee A.T., Lu Y., Remmers E.F., Kastner D.L., et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat. Genet. 2009, 41:820-823.
77. Stahl E.A., Raychaudhuri S., Remmers E.F., Xie G., Eyre S., Thomson B.P., et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 2010, 42:508-514.
78. Plagnol V., Howson J.M., Smyth D.J., Walker N., Hafler J.P., Wallace C., et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet. 2011, 7:e1002216.
79. Fanciulli M., Norsworthy P.J., Petretto E., Dong R., Harper L., Kamesh L., et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 2007, 39:721-723.
80. Anderson C.A., Boucher G., Lees C.W., Franke A., D'Amato M., Taylor K.D., et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 2011, 43:246-252.
81. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
82. Floto R.A., Clatworthy M.R., Heilbronn K.R., Rosner D.R., MacAry P.A., Rankin A., et al. Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 2005, 11:1056-1058.
83. Kono H., Kyogoku C., Suzuki T., Tsuchiya N., Honda H., Yamamoto K., et al. FcgammaRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 2005, 14:2881-2892.
84. van der Slik A.R., Koeleman B.P., Verduijn W., Bruining G.J., Roep B.O., Giphart M.J. KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 2003, 52:2639-2642.
85. Espeli M., Niederer H.A., Traherne J.A., Trowsdale J., Smith K.G. Genetic variation, Fcgamma receptors, KIRs and infection: the evolution of autoimmunity. Curr. Opin. Immunol. 2010, 22:715-722.
86. Armstrong D.L., Reiff A., Myones B.L., Quismorio F.P., Klein-Gitelman M., McCurdy D., et al. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 2009, 10:446-456.
87. Nejentsev S., Walker N., Riches D., Egholm M., Todd J.A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009, 324:387-389.
88. Hill R.J., Zozulya S., Lu Y.L., Ward K., Gishizky M., Jallal B. The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp. Hematol. 2002, 30:237-244.
89. Franke A., McGovern D.P., Barrett J.C., Wang K., Radford-Smith G.L., Ahmad T., et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 2010, 42:1118-1125.
90. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 2004, 36:337-338.
91. Martin J.E., Broen J.C., Carmona F.D., Teruel M., Simeon C.P., Vonk M.C., et al. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association study follow-up. Hum. Mol. Genet. 2012, 21:2825-2835.
92. Manjarrez-Orduno N., Marasco E., Chung S.A., Katz M.S., Kiridly J.F., Simpfendorfer K.R., et al. CSK regulatory polymorphism is associated with systemic lupus erythematosus and influences B-cell signaling and activation. Nat. Genet. 2012, 44:1227-1230.
93. Vang T., Liu W.H., Delacroix L., Wu S., Vasile S., Dahl R., et al. LYP inhibits T-cell activation when dissociated from CSK. Nat. Chem. Biol. 2012, 8:437-446.
94. Vang T., Congia M., Macis M.D., Musumeci L., Orru V., Zavattari P., et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 2005, 37:1317-1319.
95. Habib T., Funk A., Rieck M., Brahmandam A., Dai X., Panigrahi A.K., et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J. Immunol. 2012, 188:487-496.
96. Rieck M., Arechiga A., Onengut-Gumuscu S., Greenbaum C., Concannon P., Buckner J.H. Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. J. Immunol. 2007, 179:4704-4710.
97. Zikherman J., Hermiston M., Steiner D., Hasegawa K., Chan A., Weiss A. PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J. Immunol. 2009, 182:4093-4106.
98. Zhang J., Zahir N., Jiang Q., Miliotis H., Heyraud S., Meng X., et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat. Genet. 2011, 43:902-907.
99. Cambier J.C. Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways. J. Clin. Invest. 2013, 1-4.
100. Dai X., James R.G., Habib T., Singh S., Jackson S., Khim S., et al. A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. J. Clin. Invest. 2013, 123(5):2024-2036.
101. Horton H.M., Chu S.Y., Ortiz E.C., Pong E., Cemerski S., Leung I.W., et al. Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J. Immunol. 2011, 186:4223-4233.
102. Yu X., Harden K., Gonzalez L.C., Francesco M., Chiang E., Irving B., et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 2009, 10:48-57.
103. Boles K.S., Vermi W., Facchetti F., Fuchs A., Wilson T.J., Diacovo T.G., et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur. J. Immunol. 2009, 39:695-703.
104. Privratsky J.R., Newman D.K., Newman P.J. PECAM-1: conflicts of interest in inflammation. Life Sci. 2010, 87:69-82.
105. Thomas R., Matthias T., Witte T. Leukocyte immunoglobulin-like receptors as new players in autoimmunity. Clin. Rev. Allergy Immunol. 2010, 38:159-162.
106. Riella L.V., Paterson A.M., Sharpe A.H., Chandraker A. Role of the PD-1 pathway in the immune response. Am. J. Transplant. 2012, 12:2575-2587.
107. Shang Y.J., Cui Q.F., Li J.L., Guo G.N., Zhu W.Y. Expression of the costimulatory molecule BTLA in synovial tissues from rheumatoid arthritis patients. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012, 28:643-646.
108. Sui L., Li N., Liu Q., Zhang W., Wan T., Wang B., et al. IgSF13, a novel human inhibitory receptor of the immunoglobulin superfamily, is preferentially expressed in dendritic cells and monocytes. Biochem. Biophys. Res. Commun. 2004, 319:920-928.
109. Anderson A.C., Anderson D.E., Bregoli L., Hastings W.D., Kassam N., Lei C., et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
110. Lobo E.O., Zhang Z., Shively J.E. Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner. J. Leukoc. Biol. 2009, 86:205-218.
111. Adams S., van der Laan L.J., Vernon-Wilson E., Renardel de L.C., Dopp E.A., Dijkstra C.D., et al. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J. Immunol. 1998, 161:1853-1859.
112. Meyaard L. The inhibitory collagen receptor LAIR-1 (CD305). J. Leukoc. Biol. 2008, 83:799-803.
113. Bhat R., Eissmann P., Endt J., Hoffmann S., Watzl C. Fine-tuning of immune responses by SLAM-related receptors. J. Leukoc. Biol. 2006, 79:417-424.
114. Van B J., Koning F. The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology 2010, 131:301-309.
115. Dorner T., Shock A., Smith K.G. CD22 and autoimmune disease. Int. Rev. Immunol. 2012, 31:363-378.
116. Kerscher B., Willment J.A., Brown G.D. The Dectin-2 family of C-type lectin-like receptors: an update. Int. Immunol. 2013, 25:271-277.
117. Borrego F., Kabat J., Sanni T.B., Coligan J.E. NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes. J. Immunol. 2002, 169:6102-6111.
118. Lane P. Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86. Ann. N. Y. Acad. Sci. 1997, 815:392-400.
119. Holmannova D., Kolackova M., Kondelkova K., Kunes P., Krejsek J., Andrys C. CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; part I: CD200/CD200R structure, activation, and function. Acta Med. (Hradec Kralove) 2012, 55:12-17.